Ku CS, Loy EY, Salim A, Pawitan Y, Chia KS. The discovery of human genetic variations and their use as disease markers: past, present and future. J Hum Genet. 2010;55:403–15.

Article  PubMed  Google Scholar 

Thavaneswaran S, Rath E, Tucker K, Joshua AM, Hess D, Pinese M, et al. Therapeutic implications of germline genetic findings in cancer. Nat Rev Clin Oncol. 2019;16:386–96.

Article  CAS  PubMed  Google Scholar 

Wu D, Dou J, Chai X, Bellis C, Wilm A, Shih CC, et al. Large-scale whole-genome sequencing of three diverse asian populations in Singapore. Cell. 2019;179:736–49.e15.

Article  CAS  PubMed  Google Scholar 

Marum JE, Yeung DT, Purins L, Reynolds J, Parker WT, Stangl D, et al. ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure. Blood Adv. 2017;1:1369–81.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Menden MP, Casale FP, Stephan J, Bignell GR, Iorio F, McDermott U, et al. The germline genetic component of drug sensitivity in cancer cell lines. Nat Commun. 2018;9:3385.

Article  PubMed  PubMed Central  Google Scholar 

Yang H, Zhang H, Luan Y, Liu T, Yang W, Roberts KG, et al. Noncoding genetic variation in GATA3 increases acute lymphoblastic leukemia risk through local and global changes in chromatin conformation. Nat Genet. 2022;54:170–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chan SH, Bylstra Y, Teo JX, Kuan JL, Bertin N, Gonzalez-Porta M, et al. Analysis of clinically relevant variants from ancestrally diverse Asian genomes. Nat Commun. 2022;13:6694.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ng KP, Hillmer AM, Chuah CT, Juan WC, Ko TK, Teo AS, et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med. 2012;18:521–8.

Article  CAS  PubMed  Google Scholar 

Soh SX, Siddiqui FJ, Allen JC, Kim GW, Lee JC, Yatabe Y, et al. A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer. Oncotarget. 2017;8:41474–86.

Article  PubMed  PubMed Central  Google Scholar 

Cardona AF, Rojas L, Wills B, Arrieta O, Carranza H, Vargas C, et al. BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations. Oncotarget. 2016;7:68933–42.

Article  PubMed  PubMed Central  Google Scholar 

Costa DB, Halmos B, Kumar A, Schumer ST, Huberman MS, Boggon TJ, et al. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med. 2007;4:1669–79.

Article  CAS  PubMed  Google Scholar 

Cragg MS, Jansen ES, Cook M, Harris C, Strasser A, Scott CL. Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J Clin Invest. 2008;118:3651–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu J, Bhadra M, Sinnakannu JR, Yue WL, Tan CW, Rigo F, et al. Overcoming imatinib resistance conferred by the BIM deletion polymorphism in chronic myeloid leukemia with splice-switching antisense oligonucleotides. Oncotarget. 2017;8:77567–85.

Article  PubMed  PubMed Central  Google Scholar 

Ciechomska IA, Gielniewski B, Wojtas B, Kaminska B, Mieczkowski J. EGFR/FOXO3a/BIM signaling pathway determines chemosensitivity of BMP4-differentiated glioma stem cells to temozolomide. Exp Mol Med. 2020;52:1326–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Song T, Guo Y, Xue Z, Guo Z, Wang Z, Lin D, et al. Small-molecule inhibitor targeting the Hsp70-Bim protein-protein interaction in CML cells overcomes BCR-ABL-independent TKI resistance. Leukemia. 2021;35:2862–74.

Article  CAS  PubMed  Google Scholar 

Katagiri S, Umezu T, Ohyashiki JH, Ohyashiki K. The BCL2L11 (BIM) deletion polymorphism is a possible criterion for discontinuation of imatinib in chronic myeloid leukaemia patients. Br J Haematol. 2013;160:269–71.

Article  CAS  PubMed  Google Scholar 

Than H, Lye WK, Sng C, Allen JC Jr., Ong ST, Chuah C. BIM deletion polymorphism profiling complements prognostic values of risk scores in imatinib-treated Asian chronic myeloid leukemia patients. Leuk Lymphoma. 2019;60:234–7.

Article  CAS  PubMed  Google Scholar 

Vetrie D, Helgason GV, Copland M. The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML. Nat Rev Cancer. 2020;20:158–73.

Article  CAS  PubMed  Google Scholar 

Su H, Trombly MI, Chen J, Wang X. Essential and overlapping functions for mammalian Argonautes in microRNA silencing. Genes Dev. 2009;23:304–17.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pernaute B, Spruce T, Smith KM, Sanchez-Nieto JM, Manzanares M, Cobb B, et al. MicroRNAs control the apoptotic threshold in primed pluripotent stem cells through regulation of BIM. Genes Dev. 2014;28:1873–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bouillet P, Metcalf D, Huang DC, Tarlinton DM, Kay TW, Kontgen F, et al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science. 1999;286:1735–8.

Article  CAS  PubMed  Google Scholar 

Kuribara R, Honda H, Matsui H, Shinjyo T, Inukai T, Sugita K, et al. Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors. Mol Cell Biol. 2004;24:6172–83.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kozuma Y, Ninomiya H, Murata S, Kono T, Mukai HY, Kojima H. The pro-apoptotic BH3-only protein Bim regulates cell cycle progression of hematopoietic progenitors during megakaryopoiesis. J Thromb Haemost. 2010;8:1088–97.

Article  CAS  PubMed  Google Scholar 

Labi V, Bertele D, Woess C, Tischner D, Bock FJ, Schwemmers S, et al. Haematopoietic stem cell survival and transplantation efficacy is limited by the BH3-only proteins Bim and Bmf. EMBO Mol Med. 2013;5:122–36.

Article  CAS  PubMed  Google Scholar 

Leidy-Davis T, Cheng K, Goodwin LO, Morgan JL, Juan WC, Roca X, et al. Viable mice with extensive gene humanization (25-kbp) created using embryonic stem cell/blastocyst and CRISPR/Zygote injection approaches. Sci Rep. 2018;8:15028.

Article  PubMed  PubMed Central  Google Scholar 

Koschmieder S, Gottgens B, Zhang P, Iwasaki-Arai J, Akashi K, Kutok JL, et al. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. Blood. 2005;105:324–34.

Article  CAS  PubMed  Google Scholar 

Zhang B, Ho YW, Huang Q, Maeda T, Lin A, Lee SU, et al. Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. Cancer Cell. 2012;21:577–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Butow M, Testaquadra FJ, Baumeister J, Maie T, Chatain N, Jaquet T, et al. Targeting cytokine-induced leukemic stem cell persistence in chronic myeloid leukemia by IKK2-inhibition. Haematologica. 2023;108:1179–85.

Article  PubMed  Google Scholar 

Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL, Le Toumelin-Braizat G, et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature. 2016;538:477–82.

Article  PubMed